Search results
Showing 346 to 360 of 913 results for death
This guidance has been updated and replaced by NICE interventional procedures guidance 603.
This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.
View quality statements for QS23Show all sections
Sections for QS23
- Quality statements
- Quality statement 1: Needle and syringe programmes
- Quality statement 2: Assessment
- Quality statement 3: Families and carers
- Quality statement 4: Blood-borne viruses
- Quality statement 5: Information and advice
- Quality statement 6: Keyworking – psychosocial interventions
- Quality statement 7: Recovery and reintegration
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)
Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.
High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype
Evidence-based recommendations on percutaneous endoscopic colostomy. This involves placing a plastic tube in the bowel that runs back through a small opening in the abdomen to allow waste to pass through to a drainage bag worn outside the body.
View recommendations for IPG161Show all sections
Sections for IPG161
Transcatheter aortic valve implantation for aortic stenosis (IPG586)
Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for aortic stenosis. This involves inserting a new valve through a catheter, usually by way of a large blood vessel at the top of the leg, into the heart and inside the existing faulty valve.
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.
Evidence-based recommendations on the Foker technique for long-gap oesophageal atresia. This involves pulling slightly on the broken ends of the oesophagus to encourage them to grow towards each other so they can be stitched together to form a complete oesophagus.
View recommendations for IPG153Show all sections
Sections for IPG153
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
Evidence-based recommendations on endoscopic transluminal pancreatic necrosectomy in adults. This involves removing dead tissue from the pancreas.
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.